» Articles » PMID: 7871570

Tolerance Induction in a Fully Allogeneic Combination Using Anti-T Cell Receptor-alpha Beta Monoclonal Antibody, Low Dose Irradiation, and Donor Bone Marrow Transfusion

Overview
Journal Transplantation
Specialty General Surgery
Date 1995 Feb 15
PMID 7871570
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

In a murine strain combination disparate in both H-2 antigens and minor histocompatibility antigens consisting of C57BL/6 (B6; H-2b, Mls-1b) mice as recipients and AKR/J (AKR; H-2k, Mls-1a) mice as donors, we reported that the administration of anti-TCR-alpha beta mAb nonspecifically suppresses the ability to reject allografts. However, such an effect was only temporary and all grafts were eventually rejected within 40 days in the anti-TCR-alpha beta mAb-treated mice. In this study, to induce donor-specific tolerance, the transfer of donor bone marrow cells was added to the administration of anti-TCR-alpha beta mAb but donor bone marrow cells were rejected and failed to cause donor-specific unresponsiveness. After donor bone marrow cell transfer in the anti-TCR-alpha beta mAb-treated mice, the B cells of the recipients were observed along with the production of antidonor antibody. To abolish the residual lymphocyte populations, low dose irradiation was also added. A long-lasting skin allograft tolerance can be achieved by the tolerance system, in which low dose irradiation was added to the combined treatment with anti-TCR-alpha beta mAb and transfer of donor bone marrow cells. Such a protocol also established central and peripheral chimerism, which suggests that hematopoietic chimerism is necessary to maintain the tolerance. B cells were completely abolished in recipients given this combined treatment and their antibody production against donor antigens after the transfer of donor bone marrow cells was also completely suppressed. A possible role of B cells in the rejection of donor bone marrow cells before the establishment of chimerism is discussed.

Citing Articles

In Vivo Growing of New Cell Colonies in a Portion of Bone Marrow: Potential Use for Indirect Cell Therapy.

Manzanedo A, Rodriguez F, Obeso J, Rodriguez M Cell Med. 2016; 1(2):93-103.

PMID: 26966633 PMC: 4776168. DOI: 10.3727/215517910X528969.


Alloreactive Regulatory T Cells Allow the Generation of Mixed Chimerism and Transplant Tolerance.

Ruiz P, Maldonado P, Hidalgo Y, Sauma D, Rosemblatt M, Bono M Front Immunol. 2015; 6:596.

PMID: 26635810 PMC: 4655502. DOI: 10.3389/fimmu.2015.00596.


The road to purified hematopoietic stem cell transplants is paved with antibodies.

Logan A, Weissman I, Shizuru J Curr Opin Immunol. 2012; 24(5):640-8.

PMID: 22939368 PMC: 5061494. DOI: 10.1016/j.coi.2012.08.002.


T10B9 monoclonal antibody: a short-acting nonstimulating monoclonal antibody that spares gammadelta T-cells and treats and prevents cellular rejection.

Waid T, Thompson J, Siemionow M, Brown S Drug Des Devel Ther. 2009; 3:205-12.

PMID: 19920935 PMC: 2769243. DOI: 10.2147/dddt.s2750.


Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras.

Durkin E, Jones K, Rajesh D, Shaaban A Blood. 2008; 112(13):5245-53.

PMID: 18796629 PMC: 2597617. DOI: 10.1182/blood-2007-12-128116.